DOCSLIB.ORG

Diencephalic Syndrome: a Cause of Failure to Thrive and a Model of Partial Growth Hormone Resistance

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Diencephalic Syndrome: a Cause of Failure to Thrive and a Model of Partial Growth Hormone Resistance Diencephalic Syndrome: A Cause of Failure to Thrive and a Model of Partial Growth Hormone Resistance Amy Fleischman, MD*; Catherine Brue, MD*; Tina Young Poussaint, MD‡; Mark Kieran, MD, PhD§࿣; Scott L. Pomeroy, MD, PhD࿣¶; Liliana Goumnerova, MD࿣#; R. Michael Scott, MD࿣#; and Laurie E. Cohen, MD*࿣ ABSTRACT. Diencephalic syndrome is a rare but po- total of 48 similar cases, including the 12 described tentially lethal cause of failure to thrive in infants and by Russell. Since then, several case studies have been young children. The diencephalic syndrome includes reported with similar symptoms, a few with brain clinical characteristics of severe emaciation, normal lin- tumors located in the posterior fossa.2,3 Nystagmus ear growth, and normal or precocious intellectual devel- and vomiting were also noted in the majority of opment in association with central nervous system tu- reported cases.2–5 In 1976, a review of 72 cases by mors. Our group initially described a series of 9 patients 6 with diencephalic syndrome and found a reduced prev- Burr confirmed the clinical characteristics of dience- alence of emesis, hyperalertness, or hyperactivity com- phalic syndrome. Subsequent literature has consisted pared with previous reports. Also, the tumors were found of multiple case series and case reports of this to be larger, occur at a younger age, and behave more syndrome. aggressively than similarly located tumors without dien- We reviewed the 11 cases of diencephalic syn- cephalic syndrome. We have been able to extend our drome that presented to Children’s Hospital Boston follow-up of the original patients, as well as describe 2 and Dana-Farber Cancer Institute between 1970 and additional cases. Because the mechanism of the growth 2003. Our group initially described a series of 9 pa- and endocrinologic findings in diencephalic syndrome tients with diencephalic syndrome and found a re- has not been explained, we report on these patients in duced prevalence of emesis, hyperalertness, or hy- light of current research on hypothalamic factors that 7 affect growth and weight. This study emphasizes dien- peractivity compared with previous reports. Also, cephalic syndrome as a model for additional study of the tumors were found to be larger, occur at a growth hormone resistance and metabolic regulation of younger age, and behave more aggressively than adiposity. Pediatrics 2005;115:e742–e748. URL: www. similarly located tumors without diencephalic syn- pediatrics.org/cgi/doi/10.1542/peds.2004-2237; brain tu- drome. We have been able to extend our follow-up of mors, failure to thrive, growth hormone, growth patterns. the original patients, as well as describe 2 additional cases. In our series, hyperemesis, hyperkinesis, and ABBREVIATIONS. CNS, central nervous system; GH, growth hor- nystagmus were only rarely identified despite the mone; RIA, radioimmunoassay; IRMA, immunoradiometric assay; classic presentation of emaciation, normal linear IGF-I, insulin-like growth factor-I; SDS, SD score. growth, and central nervous system (CNS) neo- plasms. Thus, CNS tumors must be considered in n 1951, Russell1 described the clinical entity of any child who presents with severe, unexplained diencephalic syndrome as profound emaciation failure to thrive with preservation of linear growth in infancy with the absence of subcutaneous adi- rate. This specific form of failure to thrive occurs in I the setting of elevated growth hormone (GH), sug- pose tissue, despite normal or slightly diminished caloric intake. Linear growth was maintained. Other gesting a model of acquired partial GH resistance, as features included locomotor overactivity, hyperalert- well as abnormalities in other related pathways. ness, hyperkinesis, and euphoria. An association was noted with neoplasms of the anterior hypothalamus. METHODS In 1972, Addy and Hudson2 reported on a series of 3 To characterize the population of patients with diencephalic syndrome, we performed a retrospective review of the clinical children and reviewed the literature to summarize a records of patients who received a diagnosis of diencephalic syn- drome at Children’s Hospital Boston and Dana-Farber Cancer From the Divisions of *Endocrinology and §Hematology and Oncology and Institute between 1970 and 2003. The Institutional Review Boards Departments of ‡Radiology, ¶Neurology, and #Neurosurgery, Children’s of both institutions approved the study. Eleven patients met cri- Hospital, Boston, Massachusetts; and ࿣Department of Pediatric Oncology, teria for diencephalic syndrome with hypothalamic neoplasms Dana-Farber Cancer Institute, Boston, Massachusetts. and failure to thrive in the setting of normal developmental mile- Accepted for publication Dec 16, 2004. stones and continued age-appropriate linear growth. All patients doi:10.1542/peds.2004-2237 had initially been brought to medical attention for failure to gain No conflict of interest declared. weight appropriately and were subsequently found to have CNS Dr Brue’s current address is Department of Pediatrics, Centre Hospitalo- tumors. None of the patients had neurofibromatosis type 1. Universitaire Timone, Marseille, France. Some endocrine evaluation was performed for all of the pa- Address correspondence to Laurie E. Cohen, MD, Division of Endocrinol- tients. All assays were performed at the Children’s Hospital Bos- ogy, Children’s Hospital Boston, 300 Longwood Ave, Boston, MA 02115. ton endocrine laboratory, except where specified. Children’s Hos- E-mail: [email protected] pital Boston has used various hormone assays over the 34-year PEDIATRICS (ISSN 0031 4005). Copyright © 2005 by the American Acad- study period. GH was assayed by radioimmunoassay (RIA) until emy of Pediatrics. 1987; by immunoradiometric assay (IRMA; Nichols Institute, San e742 PEDIATRICS Vol. 115Downloaded No. 6 June from 2005www.aappublications.org/newswww.pediatrics.org/cgi/doi/10.1542/peds.2004-2237 by guest on October 1, 2021 Juan Capistrano, CA) until July 1, 1995; and by DELFIA (Perkin tricular size was noted in 6 (55%) of 11 of our pa- Elmer, Perkins Institute, Norwalk, CT), a fluorometric assay tients, similar to previously published reports of 33% method, and then Auto DELFIA between July 1, 1995 and October 4,8 31, 1996. The Nichols IRMA was used again until 1999, when the to 58%. Only 1 of the 4 patients with vomiting had Nichols Advantage Analyzer replaced it. Cortisol was assayed by hydrocephalus on the initial imaging study. There- RIA until May 1, 1994, by DELFIA until May 8, 1996, and by an fore, the presence of vomiting was not explained by immunoassay (Bayer Diagnostics, Tarrytown, NY) since May 9, an increase in intracranial pressure at the time of 1996. Insulin-like growth factor-I (IGF-1) was sent to Endocrine diagnosis in the majority of patients. Sciences until July, 1988, then measured by the Children’s Hospi- tal Boston endocrine laboratory by RIA (Nichols Institute) until Earlier case series found nystagmus to be a com- 1999, followed by the Nichols Advantage Analyzer to present. mon presenting symptom in diencephalic syndrome. Thyrotropin was assayed by IRMA (Nichols Institute). Thyroxine In our series, nystagmus was present in only 3 pa- was assayed by RIA (Nichols Institute) until 1991, by DELFIA tients. One of these 3 patients had papilledema at until 1996, and by immunoassay until the present. Growth data were analyzed according to the Centers for Disease Control and presentation. This patient was also 1 of the 6 patients Prevention 2000 standards using STAT GrowthCharts, Version 2.0 who had hydrocephalus on neuroimaging. The other (www.statcoder.com) to calculate percentiles and SD scores (SDS). 8 (73%) patients had normal ophthalmologic evalu- ations. The 3 patients with nystagmus at presentation RESULTS and 1 of the other patients eventually progressed to Between 1970 and 2003, 11 children presented to have significant visual loss. Two of these 4 patients Children’s Hospital Boston and the Dana-Farber were evaluated with full dilated ophthalmologic Cancer Institute with extreme failure to thrive and evaluation and found to have mild optic pallor, 1 at were found to have CNS neoplasms. This group presentation and 1 at a later evaluation. consisted of 5 girls and 6 boys. At presentation, 10 of the 11 patients had weights The median age at diagnosis was 18 months Ͼ2 SD below the mean for age (mean: Ϫ2.8; range: (range: 4–56 months; mean: 23 months). The dura- Ϫ0.73 to Ϫ3.89), and the 1 patient who was not tion of failure to thrive as defined by minimal or no significantly underweight (SDS: Ϫ0.73) was signifi- weight gain was a mean of 12.5 months (range: 2–33 cantly underweight for height (SDS: Ϫ2.41). The months). Two of the patients had previously re- weight-for-height measurements were Ͼ2 SD below ceived a diagnosis of reflux as a cause for their failure the mean for age in all 11 patients studied (SDS to thrive. One patient had been treated for celiac range: Ϫ2.41 to Ϫ8.72). The heights at diagnosis all disease, and 1 was assumed to have lipodystrophy. were within normal range for age (range: 10% to Previous alternative diagnoses were not correlated 97%; SDS: Ϫ1.27 to 1.90). Five (45%) of the 11 patients with a longer duration of symptoms before discovery were above the mean for age in height (Table 1). of the CNS neoplasm and confirmation of dience- Figure 1 shows examples of growth charts in 2 of phalic syndrome. these patients, demonstrating a relatively preserved Original reports of the diencephalic syndrome de- linear growth rate in the setting of poor weight gain scribed characteristic locomotor hyperactivity. How- or weight loss. Of note, patient B, who had dramatic ever, in the 11 patients in our study, hyperkinesis weight loss, eventually had some slowing of her was reported in only 1 (9%), whereas 3 patients (27%) growth rate. were actually described as lethargic by caregivers. Some endocrinologic evaluation was pursued in The 3 lethargic patients did have mild to moderate all patients before initiation of therapy for the intra- hydrocephalus at presentation (see below), but the cranial neoplasm.
Load more

Recommended publications
  • Pyrexia of Unknown Origin. Presenting Sign of Hypothalamic Hypopituitarism R
    Postgrad Med J: first published as 10.1136/pgmj.57.667.310 on 1 May 1981. Downloaded from Postgraduate Medical Journal (May 1981) 57, 310-313 Pyrexia of unknown origin. Presenting sign of hypothalamic hypopituitarism R. MARILUS* A. BARKAN* M.D. M.D. S. LEIBAt R. ARIE* M.D. M.D. I. BLUM* M.D. *Department of Internal Medicine 'B' and tDepartment ofEndocrinology, Beilinson Medical Center, Petah Tiqva, The Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel Summary least 10 such admissions because offever of unknown A 62-year-old man was admitted to hospital 10 times origin had been recorded. During this period, he over 12 years because of pyrexia of unknown origin. was extensively investigated for possible infectious, Hypothalamic hypopituitarism was diagnosed by neoplastic, inflammatory and collagen diseases, but dynamic tests including clomiphene, LRH, TRH and the various tests failed to reveal the cause of theby copyright. chlorpromazine stimulation. Lack of ACTH was fever. demonstrated by long and short tetracosactrin tests. A detailed past history of the patient was non- The aetiology of the disorder was believed to be contributory. However, further questioning at a previous encephalitis. later period of his admission revealed interesting Following substitution therapy with adrenal and pertinent facts. Twelve years before the present gonadal steroids there were no further episodes of admission his body hair and sex activity had been fever. normal. At that time he had an acute febrile illness with severe headache which lasted for about one Introduction week. He was not admitted to hospital and did not http://pmj.bmj.com/ Pyrexia of unknown origin (PUO) may present receive any specific therapy.
    [Show full text]
  • Hypothalamic Hamartoma
    Neurol Med Chir (Tokyo) 45, 221¿231, 2005 Hypothalamic Hamartoma Kazunori ARITA,KaoruKURISU, Yoshihiro KIURA,KojiIIDA*, and Hiroshi OTSUBO* Department of Neurosurgery, Graduate School of Biomedical Science, Hiroshima University, Hiroshima; *Division of Neurology, The Hospital for Sick Children, Toronto, Ontario, Canada Abstract The incidence of hypothalamic hamartomas (HHs) has increased since the introduction of magnetic resonance (MR) imaging. The etiology of this anomaly and the pathogenesis of its peculiar symptoms remain unclear, but recent electrophysiological, neuroimaging, and clinical studies have yielded important data. Categorizing HHs by the degree of hypothalamic involvement has contributed to the accurate prediction of their prognosis and to improved treatment strategies. Rather than undergoing corticectomy, HH patients with medically intractable seizures are now treated with surgery that targets the HH per se, e.g. HH removal, disconnection from the hypothalamus, stereotactic irradiation, and radiofrequency lesioning. Although surgical intervention carries risks, total eradication or disconnec- tion of the lesion leads to cessation or reduction of seizures and improves the cognitive and behavioral status of these patients. Precocious puberty in HH patients is safely controlled by long-acting gonadotropin-releasing hormone agonists. The accumulation of knowledge regarding the pathogenesis of symptoms and the development of safe, effective treatment modalities may lead to earlier interven- tion in young HH patients and prevent
    [Show full text]
  • Pediatric Neuro-Ophthalmology
    Pediatric Neuro-Ophthalmology Second Edition Michael C. Brodsky Pediatric Neuro-Ophthalmology Second Edition Michael C. Brodsky, M.D. Professor of Ophthalmology and Neurology Mayo Clinic Rochester, Minnesota USA ISBN 978-0-387-69066-7 e-ISBN 978-0-387-69069-8 DOI 10.1007/978-0-387-69069-8 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2010922363 © Springer Science+Business Media, LLC 2010 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connec-tion with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not ­identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with re-spect to the material contained herein. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com) To the good angels in my life, past and present, who lifted me on their wings and carried me through the storms.
    [Show full text]
  • NEUROLOGY in TABLE.Pdf
    ZAPORIZHZHIA STATE MEDICAL UNIVERSITY DEPARTMENT OF NEUROLOGY DISEASES NEUROLOGY IN TABLE (General neurology) for practical employments to the students of the IV course of medical faculty Zaporizhzhia, 2015 2 It is approved on meeting of the Central methodical advice Zaporozhye state medical university (the protocol № 6, 20.05.2015) and is recommended for use in scholastic process. Authors: doctor of the medical sciences, professor Kozyolkin O.A. candidate of the medical sciences, assistant professor Vizir I.V. candidate of the medical sciences, assistant professor Sikorskaya M.V. Kozyolkin O. A. Neurology in table (General neurology) : for practical employments to the students of the IV course of medical faculty / O. A. Kozyolkin, I. V. Vizir, M. V. Sikorskaya. – Zaporizhzhia : [ZSMU], 2015. – 94 p. 3 CONTENTS 1. Sensitive function …………………………………………………………………….4 2. Reflex-motor function of the nervous system. Syndromes of movement disorders ……………………………………………………………………………….10 3. The extrapyramidal system and syndromes of its lesion …………………………...21 4. The cerebellum and it’s pathology ………………………………………………….27 5. Pathology of vegetative nervous system ……………………………………………34 6. Cranial nerves and syndromes of its lesion …………………………………………44 7. The brain cortex. Disturbances of higher cerebral function ………………………..65 8. Disturbances of consciousness ……………………………………………………...71 9. Cerebrospinal fluid. Meningealand hypertensive syndromes ………………………75 10. Additional methods in neurology ………………………………………………….82 STUDY DESING PATIENT BY A PHYSICIAN NEUROLOGIST
    [Show full text]
  • Diencephalic Syndrome: a Cause of Failure to Thrive and a Model of Partial Growth Hormone Resistance
    Diencephalic Syndrome: A Cause of Failure to Thrive and a Model of Partial Growth Hormone Resistance Amy Fleischman, MD*; Catherine Brue, MD*; Tina Young Poussaint, MD‡; Mark Kieran, MD, PhD§࿣; Scott L. Pomeroy, MD, PhD࿣¶; Liliana Goumnerova, MD࿣#; R. Michael Scott, MD࿣#; and Laurie E. Cohen, MD*࿣ ABSTRACT. Diencephalic syndrome is a rare but po- total of 48 similar cases, including the 12 described tentially lethal cause of failure to thrive in infants and by Russell. Since then, several case studies have been young children. The diencephalic syndrome includes reported with similar symptoms, a few with brain clinical characteristics of severe emaciation, normal lin- tumors located in the posterior fossa.2,3 Nystagmus ear growth, and normal or precocious intellectual devel- and vomiting were also noted in the majority of opment in association with central nervous system tu- reported cases.2–5 In 1976, a review of 72 cases by mors. Our group initially described a series of 9 patients 6 with diencephalic syndrome and found a reduced prev- Burr confirmed the clinical characteristics of dience- alence of emesis, hyperalertness, or hyperactivity com- phalic syndrome. Subsequent literature has consisted pared with previous reports. Also, the tumors were found of multiple case series and case reports of this to be larger, occur at a younger age, and behave more syndrome. aggressively than similarly located tumors without dien- We reviewed the 11 cases of diencephalic syn- cephalic syndrome. We have been able to extend our drome that presented to Children’s Hospital Boston follow-up of the original patients, as well as describe 2 and Dana-Farber Cancer Institute between 1970 and additional cases.
    [Show full text]
  • Acoustic Neurinoma. See Vestibular Schwannomas Acquired
    3601_e28index_p591-606 2/19/02 9:09 AM Page 591 Index Page numbers followed by “f” indicate figures; numbers followed by “t” indicate tables; “CF” indicates color figures. Acoustic neurinoma. See Vestibular schwannomas Amenorrhea-galactorrhea syndrome, 168 Acquired immunodeficiency disease (AIDS) Amifostine and neuroprotection, 407 lymphomatous meningitis and, 376 Amputation and cancer pain, 506–7 Acromegaly, 210 Amyloid neuropathy, 402 Acroparesthesia, 398 Analgesics. See also Cancer pain Acute radiation syndrome, 574–75 adjuvant drugs, 517t–518t, 524–25 Addiction and opioid analgesics, 523 nonopioid, 510–11, 510t Adenocarcinoma of anterior skull base, 316 opioid. See Opioid analgesics Adenohypophysis, 208. See also Pituitary tumors Anemia and behavioral changes, 560 Adenoid cystic carcinoma of anterior skull base, 316 Aneurysms, neoplastic, 457 Adenoma sebaceum and tuberous sclerosis, 96 Angiography, cerebral, 282–84, 283f Adenomas. See also Pituitary tumors Angiomas, cavernous, 20–21 imaging, 11, 14f Antibodies and paraneoplastic neurologic disease, 424, 425t Adjustment disorders, 578–79. See also Psychological issues Anticonvulsants, 576. See also Seizure, treatment for cancer pain, prevalence, 573 524–25 Adjuvant drugs. See also specific medications neurobehavioral changes, 560 adverse effects of, 559–60 Antidepressants, 579–81, 579t analgesic, 517t–518t, 524–25 Antiemetics Adrenal dysfunction after cancer treatment, 540 and seizures, 441 Adrenocorticotropin (ACTH) and syncope, 448 after cancer treatment, 538 Antihistamines and brain
    [Show full text]
  • Opsoclonus-Myoclonus Presenting with Features of Spasmus Nutans
    67 References scans of the brain were normal, and cerebrospinal fluid was acellular, 1. Balk R, Hiller C, Lucas EA, et al: Sleep apnea and the Arnold Chiari with normal chemistries. A 24-hour urine collection revealed vanilmandel- malformation. Am Rev Respir Dis 1985;132:929-930. ic acid, 1.9 mg/total volume (normal, 1 to 1.5 mg); homovanillic acid, 1.4 2. Ruff ME, Oakes WJ, Fisher SR, Spock A: Sleep apnea and vocal mg/total volume (normal, 0 to 4 mg); homovanillic acid/creatinine ratio, cord paralysis secondary to type I Chiari malformation. Pediatrics 17 mg/g of creatinine (normal, < 35 mg/g); epinephrine, 7.0 ug/tota.l volume 1987;80:231-234. (normal, 0 to 5.0 ug); and norepinephrine, 8.0 ug/total volume (normal, 0 3. Levitt P, Cohen MA: Sleep apnea and the Chiari I malformation: to 20 ug). Chest and abdominal computed tomographic and radiolabeled Case report. Neurosurgery 1988;23:508-510. metaiodobenzylguanidine scan did not show neuroblastoma. 4. Langevin B, Sukkar F, Leger P, et al: Sleep apnea syndromes (SAS) The child’s head tremor worsened over the ensuing 2 weeks to the of specific etiology: Review and incidence from a sleep laboratory. point of interfering with her sleep. Her parents now noted large involun- Sleep 1992;15:S25-S32. tary eye movements, increasing unsteadiness, and rapid jerking of the 5. White DP: Central sleep apnea, in Kryger MH, Roth T, Dement WC extremities that interrupted her attempts at feeding. Examination (eds): Principles and Practice of Sleep Medicine. Philadelphia, WB showed rapid, continuous horizontal, vertical, and oblique conjugate eye Saunders, 1989, pp 513-524.
    [Show full text]
  • Indian Journal of Practical
    INDIAN JOURNAL OF PRACTICAL PEDIATRICS • IJPP is a quarterly subscription journal of the Indian Academy of Pediatrics committed to presenting practical pediatric issues and management updates in a simple and clear manner • Indexed in Excerpta Medica, CABI Publishing, Scopus Vol.18 No.2 APR.- JUN. 2016 Dr.P.Ramachandran Dr.S.Thangavelu Editor-in-Chief Executive Editor CONTENTS TOPIC OF INTEREST - “PEDIATRIC NEUROLOGY” Approach to a child with acute flaccid paralysis 101 - Naveen Sankhyan, Renu Suthar Approach to a child with ataxia 109 - Leema Pauline C, Viveha Saravanan R, Ravi LA Pediatric CNS demyelinating disorders - An update 122 - Lokesh Lingappa, Nikit Milind Shah, Approach to muscle disorders in childhood 136 - Viswanathan V Hydrocephalus 144 - Hari VS, Thiagarajan G, Lakshmi Tilak S Epileptic encephalopathies in children 151 - Vinayan KP Neurometabolic disorders: A diagnostic approach 158 - Bindu PS, Arun B Taly Traumatic brain injury 171 - Soonu Udani Hypoxic ischemic encephalopathy in children: An intensivist’s perspective 180 - Jayashree M, Abhijit Choudhary Childhood migraine 186 - Sangeetha Yoganathan Journal Office and address for communications: Dr. P.Ramachandran, Editor-in-Chief, Indian Journal of Practical Pediatrics, 1A, Block II, Krsna Apartments, 50, Halls Road, Egmore, Chennai - 600 008. Tamil Nadu, India. Tel.No. : 044-28190032 E.mail : [email protected] 1 Indian Journal of Practical Pediatrics 2016;18(2) : 98 GENERAL ARTICLE Unexpected difficult pediatric airway:Pearls and pitfalls for the ED physician 193
    [Show full text]
  • Biomarkers in Rare Demyelinating Disease of the Central Nervous System
    International Journal of Molecular Sciences Review Biomarkers in Rare Demyelinating Disease of the Central Nervous System Marina Boziki , Styliani-Aggeliki Sintila, Panagiotis Ioannidis and Nikolaos Grigoriadis * 2nd Neurological University Department, Aristotle University of Thessaloniki, AHEPA General Hospital, 54634 Thessaloniki, Greece; [email protected] (M.B.); [email protected] (S.-A.S.); [email protected] (P.I.) * Correspondence: [email protected]; Tel.: +30-2310994683 Received: 14 October 2020; Accepted: 7 November 2020; Published: 9 November 2020 Abstract: Rare neurological diseases are a heterogeneous group corresponding approximately to 50% of all rare diseases. Neurologists are among the main specialists involved in their diagnostic investigation. At the moment, a consensus guideline on which neurologists may base clinical suspicion is not available. Moreover, neurologists need guidance with respect to screening investigations that may be performed. In this respect, biomarker research has emerged as a particularly active field due to its potential applications in clinical practice. With respect to autoimmune demyelinating diseases of the Central Nervous System (CNS), although these diseases occur in the frame of organ-specific autoimmunity, pathology of the disease itself is orchestrated among several anatomical and functional compartments. The differential diagnosis is broad and includes, but is not limited to, rare neurological diseases. Multiple Sclerosis (MS) needs to be differentially diagnosed from rare MS variants, Acute Disseminated Encephalomyelitis (ADEM), the range of Neuromyelitis Optica Spectrum Disorders (NMOSDs), Myelin Oligodendrocyte Glycoprotein (MOG) antibody disease and other systemic inflammatory diseases. Diagnostic biomarkers may facilitate timely diagnosis and proper disease management, preventing disease exacerbation due to misdiagnosis and false treatment. In this review, we will describe advances in biomarker research with respect to rare neuroinflammatory disease of the CNS.
    [Show full text]
  • Neuromyelitis Optica Spectrum Disorders
    Clinical Medicine 2019 Vol 19, No 2: 169–76 REVIEW N e u r o m y e l i t i s o p t i c a s p e c t r u m d i s o r d e r s Authors: S a i f H u d a , A D a n W h i t t a m , B M a n e e s h B h o j a k , C J a y n e C h a m b e r l a i n , D C a r m e l N o o n a n , E A n u J a c o b F , G a n d H R a c h e l K n e e n Neuromyelitis optica spectrum disorder (NMOSD) is an oedema from C1-T4 with contrast enhancement. His cerebrospinal uncommon antibody-mediated disease of the central nervous fluid demonstrated a lymphocytic pleocytosis (white cell count system. Long segments of spinal cord infl ammation (myelitis), 40 cells/mm 3 ) with normal protein, glucose ratio, and negative severe optic neuritis, and/or bouts of intractable vomiting and oligoclonal bands. Acute inflammatory transverse myelitis was hiccoughs (area postrema syndrome) are classic presentations diagnosed and he was given 1 gram of IV methylprednisolone for ABSTRACT of the disease and may alert the clinician to the diagnosis. 5 days. His serum was sent for aquaporin-4 (AQP4) and myelin Untreated, approximately 50% of NMOSD patients will be wheel- oligodendrocyte glycoprotein (MOG) antibodies (Abs).
    [Show full text]
  • Orthostatic Hypotension in an Elderly Patient
    Self-assessment corner 685 the first 4-5 years of life. However, early severe insulin resistance states. Metformin and closure ofthe epiphyses leads to a reduced final thiazolidinedione have been tried with variable height. Hyperlipidaemia may result in pancrea- results in some patients with Type B insulin Postgrad Med J: first published as 10.1136/pgmj.74.877.685 on 1 November 1998. Downloaded from titis. Polycystic ovarian syndrome with hyper- resistance syndrome.5 Insulin-like growth androgenism and irregular menses has been factor-i, a member ofthe proinsulin family, also reported.' 2 The syndromes of partial lipodys- seems to hold promise in the treatment ofsevere trophy include face-sparing lipodystrophy and insulin-resistant states.6 Topical application of cephalothoracic lipodystrophy (box 1). tretinoin cream or gel has been found to be use- The pathophysiology of these disorders is ful in controlling acanthosis nigricans.7 Virilisa- poorly understood. The currently debated theo- tion features may require spironolactone, or ries are listed in box 2. The other insulin- resist- low-dose cyproterone or oral contraceptive pills. ant states are tabulated in box 3. No therapeutic agent has been shown to be uniformly effective Final diagnosis in treating insulin resistance. The diabetic state requires high dosages (sometimes thousands of Adult-onset acquired generalised lipodystro- units per day) of insulin. When very high doses phy with insulin resistance. are needed U500 preparations may help cut down the volume ofinjection. Insulin-sensitizing Keywords: lipodystrophy syndromes; wasting; diabetes agents may have a role in the treatment of the mellitus 1 Braimon JC, Moller DE. Hereditary and acquired syn- 5 Di Paolo S.
    [Show full text]
  • Transient Cortical Blindness with Leptomeningeal Enhancement
    children with neurofibromatosis type 1: a minute. The patient’s blood pres- longitudinal study. J Pediatr. 1994;125:63- Transient Cortical Blindness sure was controlled with low-dose 66. 3. Balcer LJ, Liu GT, Heller G, et al. Visual loss With Leptomeningeal oral metoprolol. in children with neurofibromatosis type 1 and Enhancement After After the procedure, the patient optic pathway gliomas: relation to tumor lo- Attempted Peripherally complained of progressive visual cation by magnetic resonance imaging. Am J Inserted Central Venous loss, headache, and malaise, which Ophthalmol. 2001;131:442-445. progressed to complete binocular 4. Poussaint TY, Barnes PD, Nichols K, et al. Catheter Placement Diencephalic syndrome: clinical features and visual loss during the ensuing 4 imaging findings. AJNR Am J Neuroradiol. 1997; hours. Ophthalmic examination re- 18:1499-1505. Transient cortical blindness is an in- vealed no light perception vision 5. Dutton JJ. Gliomas of the anterior visual frequent complication of endovas- bilaterally and briskly reactive pu- pathway. Surv Ophthalmol. 1994;38:427-452. 1-3 6. Hoyt WF, Meshel LG, Lessell S, et al. Malig- cular procedures. We describe a pils, without a relative afferent nant optic glioma of adulthood. Brain. 1973; patient who developed transient cor- pupillary defect. The anterior seg- 96:121-132. tical blindness associated with fo- ment, extraocular motility, and di- 7. Djalilian HR, Shah MV, Hall WA. Radio- cal leptomeningeal enhancement on lated funduscopy findings were nor- graphic incidence of multicentric malignant gliomas. Surg Neurol. 1999;51:554-558. contrast-enhanced T1-weighted mal in each eye. Findings from the 8. Van Tassel P, Lee YY, Bruner JM.
    [Show full text]